Back to top
more

Alnylam Pharmaceuticals (ALNY)

(Delayed Data from NSDQ)

$273.91 USD

273.91
866,294

+7.32 (2.75%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $273.99 +0.08 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Regeneron, Sanofi Expand Investment in Cemiplimab & Dupilumab

Regeneron (REGN) and partner Sanofi announced that they will expand their investment for the development cemiplimab in oncology, and label expansion of dupilumab in Type II allergic diseases.

    Alnylam, Sanofi Announce Restructuring Deal for RNAi Products

    Alnylam (ALNY) and Sanofi entered into a strategic restructuring of their RNAi therapeutics rare genetic diseases alliance.

      4 Biotech Stocks That More Than Doubled This Year

      We take a look at a few biotech stocks whose price has increased more than 100% in 2017.

        BioMarin's (BMRN) Gene Therapy Enters First Phase III Study

        BioMarin (BMRN) commences the first phase III study to evaluate the 6e13 vg/kg dose of its investigational gene therapy, valoctocogene roxaparvovec, for severe hemophilia A.

          Why is Alnylam's (ALNY) Stock Up More Than 200% This Year?

          Alnylam's (ALNY) share price has increased year to date based on impressive progress of its pipeline candidates.

            Arpita Dutt headshot

            Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy

            A one-time gene therapy for an inherited retinal disease gained FDA approval this week while Exelixis's (EXEL) Cabometyx can now be used in treatment-naive advanced renal cell carcinoma patients.

              Alnylam/Sanofi Submit MAA in Europe for RNAi Candidate

              Alnylam (ALNY) and partner Sanofi have submitted a Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment adults with hereditary ATTR amyloidosis with polyneuropathy.

                Sanofi/Alnylam Say FDA Lifts Clinical Hold on Fitusiran

                Sanofi (SNY) and Alnylam announced that the FDA has lifted the clinical hold placed on all ongoing studies of its hemophilia candidate, fitusiran.

                  Alnylam's RNAi Candidate Gains Breakthrough Therapy Status

                  Alnylam (ALNY) announced that the FDA has granted Breakthrough Therapy Designation for RNAi therapeutic candidate, patisiran.

                    Alnylam Starts Rolling NDA Submission for RNAi Candidate

                    Alnylam (ALNY) has started rolling New Drug Application to the FDA for its RNAi candidate, patisiran.

                      Why is Alnylam's (ALNY) Stock Up More Than 200% this Year?

                      Alnylam (ALNY) expects to achieve the profile of three marketed products by the end of 2020 and remains focused on development of its pipeline candidates.

                        Alnylam RNAi Drug Gets Accelerated Assessment Grant From EMA

                        Alnylam's (ALNY) RNAi candidate, patisiran, has been granted accelerated assessment by the European Medicines Agency. The company expects to file new drug application by end of 2017.

                          Alnylam's (ALNY) Q3 Earnings, Revenues Miss Estimates

                          Alnylam Pharmaceuticals (ALNY) incurred wider than expected loss and missed sales estimates in the third quarter of 2017.

                            What's in Store for Ligand (LGND) This Earnings Season?

                            Ligand's (LGND) Captisol formulation technology that helps it form partnerships with several leading healthcare companies might drive the stock in Q3.

                              What's in Store for Madrigal (MDGL) This Earnings Season?

                              Madrigal (MDGL) expects data readout for its lead candidate MGL-3196 on its third-quarter earnings call.

                                Inovio (INO) Q3 Earnings: Is a Beat in Store for the Stock?

                                Inovio's (INO) most advanced pipeline candidate, VGX-3100 vaccine's consistent progress might drive the stock in Q3. However, lack of an approved product in the company's portfolio is a dampener.

                                  What's in Store for Catalyst (CPRX) This Earnings Season?

                                  Catalyst (CPRX) focus will be on pipeline and regulatory updates at the third-quarter earnings call.

                                    Is a Surprise Coming for Alnylam Pharmaceuticals (ALNY) This Earnings Season?

                                    Alnylam Pharmaceuticals (ALNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                                      Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 10.3% in Session

                                      Alnylam Pharmaceuticals (ALNY) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

                                        Medicines Company (MDCO) Reports Q3 Loss, Revenues Miss

                                        The Medicines Company (MDCO) incurs loss in the third quarter of 2017. The top line decreases year over year due to low Angiomax sales.

                                          Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up

                                          Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.

                                            Company News For Sep 21, 2017

                                            Companies in the news are: BBBY,FDX,ALNY,GIS

                                              Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 51.7% in Session

                                              Alnylam Pharmaceuticals (ALNY) saw a big move last session, as its shares jumped nearly 52% on the day, amid huge volumes.

                                                Calamities Couldn't Spoil The Bullish Run

                                                Calamities Couldn't Spoil The Bullish Run

                                                  Mark Vickery headshot

                                                  Hurricanes, Earthquakes and Record-High Markets

                                                  With Hurricane Maria striking Puerto Rico and two major earthquakes destroying parts of Mexico, markets continue to reach for new record highs.